
معرفی
Michal Bassani-Sternberg is an Assistant Professor on conditional pre-tenure at the Faculty of Biology and Medicine, University of Lausanne (UNIL), and an Assistant Member at the Ludwig Institute for Cancer Research, Lausanne. She leads the Antigen Discovery Group and the Immunopeptidomics Unit at the Center for Experimental Therapies, Department of Oncology, UNIL-CHUV. Her work bridges proteogenomics, mass spectrometry, and computational biology to advance personalized cancer immunotherapy.
Her educational background includes a Bachelor, Master, and Doctorate in Biology from the Technion – Israel Institute of Technology, Haifa, all earned with Cum Laude distinction. She completed postdoctoral training at the Technion and the Max Planck Institute for Biochemistry, Germany, in the group of Prof. Matthias Mann.
Dr. Bassani-Sternberg's research focuses on identifying cancer-specific Human Leukocyte Antigen (HLA) ligands to guide the development of personalized immunotherapies. Her group develops cutting-edge proteogenomic and mass spectrometry-based immunopeptidomics approaches to discover tumor-associated antigens, neoantigens, and non-canonical peptides. A key contribution is the development of NeoDisc, a continuous bioinformatics pipeline that integrates genomics, transcriptomics, and immunopeptidomics data for direct neoantigen identification in clinical trials.
Her recent publications, appearing in high-impact journals such as Nature, Nature Biotechnology, Immunity, and Nature Cancer, reflect a strong trend in integrating multi-omics data to understand tumor immunogenicity, T cell responses, and antigen presentation dynamics. Her work increasingly incorporates machine learning to improve neoantigen prediction and TCR specificity inference.
She has been recognized with the Pfizer Research Prize in 2021 for her contributions to immuno-oncology.
- Pfizer Research Prize (2021)
Dr. Bassani-Sternberg leads an active research group involved in phase I clinical trials for personalized cancer vaccines and adoptive T cell therapies. Her lab is supported by major grants from the Swiss Cancer League, Swiss National Science Foundation, and ISREC Foundation. She mentors doctoral and postdoctoral researchers and collaborates extensively within the Lausanne immuno-oncology ecosystem, including CHUV and Ludwig Lausanne.
Her lab, the Bassani-Sternberg Lab, is part of the Department of Oncology’s research platforms and focuses on immunopeptidomics, antigen discovery, and the development of analytical tools for personalized immunotherapy.





